January 18, 2022
NEW YORK (Reuters Health) – Risankizumab, an inhibitor of interleukin 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly […]
January 15, 2022
The Food and Drug Administration on Jan. 14 approved two oral JAK-1 inhibitors for patients with moderate-to-severe atopic dermatitis (AD) — upadacitinib and abrocitinib — making them […]
January 15, 2022
The Isotretinoin Products Manufacturers Group (IPMG) reports that most users of the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) should now have access to their accounts, one month after […]
January 12, 2022
An estimated 50% of children with atopic dermatitis (AD) struggle with sleep problems, with complaints that vary from sleep fragmentation to restlessness and limb movements, according […]
January 7, 2022
If you don’t think it’s important to assess for sleep disorders in your patients with atopic dermatitis (AD), think again. According to Sabra M. Abbott, MD, PhD, […]
January 6, 2022
In the opinion of Raj Chovatiya, MD, PhD, the longitudinal course of atopic dermatitis (AD) is an important yet overlooked clinical domain of the disease. Dr […]
January 5, 2022
In the clinical experience of Jonathan I. Silverberg, MD, PhD, MPH, atopic dermatitis (AD) patients with severe itch and mild to moderate lesions often fall through […]
January 4, 2022
Atopic dermatitis (AD) may be especially active and severe among older adults, and it may be associated with increased risk of comorbid conditions common in later […]
December 30, 2021
The Food and Drug Administration has accepted a new drug application (NDA) for roflumilast, a topical phosphodiesterase type 4 (PDE4) inhibitor for treating psoriasis in adults and […]